The trajectory of companies tied to the drug's legacy presents a challenging investment picture . While the initial boom generated substantial profits , generic copies have significantly impacted sales . Investing in associated pharmaceutical businesses now requires a careful assessment of intellectual property rights , evolving medical shifts , an